South Africa has launched a national rollout of Lenacapavir, a long-acting injectable designed for HIV prevention [1].
This initiative represents a significant shift in the country's public health strategy by moving away from daily medication toward a less frequent dosing schedule. The rollout aims to reduce new infections and strengthen the long-term HIV response across the nation [1, 2].
The program targets more than three million South Africans [1]. Government officials intend to reach this population within three years [1]. The medication is administered as an injection only twice a year [2].
President Cyril Ramaphosa said the rollout of Lenacapavir offers hope in the fight against HIV/AIDS [2]. He said the government is committed to ensuring that every South African who needs the injection will have access to it [1].
Health Minister Dr. Aaron Motsoaledi said the twice-yearly injectable is a game-changer in the country's prevention efforts [2]. The rollout is supported by the South African government in collaboration with Gilead Sciences and the Global Fund [3].
By reducing the frequency of doses, the government hopes to increase adherence to prevention protocols. The transition to a six-month injection cycle removes the burden of daily pill consumption, which has historically been a barrier to consistent HIV prevention [1, 2].
“The rollout of Lenacapavir offers hope in the fight against HIV/AIDS.”
The adoption of Lenacapavir marks a transition toward long-acting pharmaceuticals in the global fight against HIV. By reducing the requirement for daily adherence to a twice-yearly schedule, South Africa is attempting to overcome the logistical and behavioral hurdles that often lead to treatment failure, potentially lowering the national infection rate more effectively than traditional PrEP methods.
